Filing Details

Accession Number:
0001209191-22-023845
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-08 16:09:49
Reporting Period:
2022-04-06
Accepted Time:
2022-04-08 16:09:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Therapeutics Public Ltd Co HZNP Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1611468 W. Paul Hoelscher C/O Horizon Therapeutics Plc,
70 St. Stephen?S Green
Dublin L2 D02 E2X4
Evp, Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2022-04-06 30,275 $15.96 31,324 No 4 M Direct
Ordinary Shares Acquisiton 2022-04-06 185,060 $22.14 216,384 No 4 M Direct
Ordinary Shares Disposition 2022-04-06 215,335 $110.01 1,049 No 4 S Direct
Ordinary Shares Disposition 2022-04-06 91,710 $110.01 66,673 No 4 S Indirect By LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Indirect By LLC
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2022-04-06 30,275 $0.00 30,275 $15.96
Ordinary Shares Stock Option (Right to Buy) Disposition 2022-04-06 185,060 $0.00 185,060 $22.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-06-26 No 4 M Direct
86,424 2025-03-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 72,789 Indirect By Trust
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC.
  6. The option is fully vested and exercisable.